Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease

NCT05738486 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05738486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 28, 2023
Completion date
May 31, 2027
Enrollment
1,175 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, brain diseases, central nervous system diseases, dementia, mental disorders, nervous system diseases, neurocognitive disorders, neurodegenerative diseases